WO2000008197A1 - Method for the production of an antibiotic agent - Google Patents

Method for the production of an antibiotic agent Download PDF

Info

Publication number
WO2000008197A1
WO2000008197A1 PCT/US1999/017444 US9917444W WO0008197A1 WO 2000008197 A1 WO2000008197 A1 WO 2000008197A1 US 9917444 W US9917444 W US 9917444W WO 0008197 A1 WO0008197 A1 WO 0008197A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
proline
trace elements
production
amino acids
Prior art date
Application number
PCT/US1999/017444
Other languages
French (fr)
Inventor
Neal C. Connors
Leslie A. Petersen
David L. Hughes
Lisa M. Dimichele
Thomas J. Novak
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Priority to EP99938933A priority Critical patent/EP1100947A4/en
Priority to JP2000563820A priority patent/JP2003510245A/en
Priority to AU53311/99A priority patent/AU5331199A/en
Publication of WO2000008197A1 publication Critical patent/WO2000008197A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins

Definitions

  • the fungus Glarea lozoyensis produces a family of structurally-related, pharmaceutically-important compounds known as the pneumocandins. These acylated hexapeptides are interesting in that all the constituent amino acids contain one or more hydroxyl groups.
  • Compound I is produced by cultivating the fungus Glarea lozoyensis (formerly identified as Zalerion arboricola) under aerobic conditions. A process for the production of Compound I is disclosed in U.S. Patent 5,194,377 which issued March 16, 1993. Compound I is produced by cultivating Glarea lozoyensis, ATCC No. 20868, deposited under the Budapest Treaty in the Culture Collection of the American Type Culture Collection at 12301 Parklawn Drive, Rockville, Md. 20852.
  • the present invention relates to an improved process for the production of Compound I of the formula
  • novel compounds which are structural analogues of Compound I produced during the fermentation of Compound I. These include compounds of the formula
  • Each of the compounds (II-XII) exhibits antifungal activity.
  • the invention also relates to the use of certain amino acids, trace elements and sugar content to enhance the production of Compound I and impact the production of certain analogue impurities.
  • the fungus Glarea lozoyensis (ATCC 74030) is used to produce Compound I and the structurally related analogues.
  • This improved production strain was derived ultimately from the wild-type organism, ATCC 20868, (isolated from a sample of fresh water) by sequential steps of N-methyl-N'-nitro-iV-nitrosoguanidme mutagenesis. The culture was maintained as aliquots of a mycelial suspension in 5% (v/v) glycerol stored at -70°C.
  • compositions of the seed and production media can be composed of a variety of carbon sources, nitrogen sources, inorganic salts, and trace nutrients in a variety of proportions. Where applicable these nutrients can be organic or inorganic, simple or complex. Each nutrient is present at a concentration appropriate and in proportion to the other nutrients in the medium. Typical useful seed and production media are listed below in Table 1 and Table 2.
  • a 250 ml Erlenmeyer flask containing 50 ml of LYCP-5 medium was inoculated aseptically with 1 ml of a thawed culture stock. This first stage seed culture was incubated at 25°C with 220 rpm agitation for 3-5 days. A 1 ml aliquot of the first stage seed was transferred to a second 250 ml Erlenmeyer flask containing 50 ml of LYCP-5 medium. This second stage seed culture was incubated as above for 3 days.
  • each treatment group For each variable tested (i.e., treatment group), several 250 ml Erlenmeyer flasks each containing 25 ml FGY medium or a variation thereof (described below) were inoculated at 5% (v/v) with second stage seed. The flasks were incubated at 25°C with 220 rpm agitation for 14 days. The pH for each treatment group was adjusted as required by removing one flask from the group, adding acid or base to return the pH to 5.0-5.5, and then adding this same volume of sterile titrant to the remaining flasks in the group. Where required, a volume of a sterile fructose solution was added during the fermentation to maintain the residual concentration within a specific range.
  • Amino acids such as glutamine, arginine, and ornithine which can be metabolized to ⁇ -pyrroline-5-carboxylate (P5C) also appear to have an impact on the analogues which are defined by the specific amino acid incorporated at the position "occupied” by 3-hydroxyproline in Compound I (Table 5).
  • Table 5 Effect of proline “related” amino acids added (5 gm/L) on or about day 6.
  • osmolarity can be controlled by maintaining the residual fructose concentration at high (>75 gm/L) or low ( ⁇ 30 gm/L).
  • the initial fructose concentration in the control process is 125 gm/L and is kept high by making two 50 gm/L additions during the 14 cycle.
  • the initial fructose concentration can be lowered to 40 gm/L and several 25 gm/L additions made during the course of the fermentation to maintain a low residual sugar level.
  • hydroxylation patterns of amino acids of Compound I are sensitive to zinc, cobalt and nickel. Additionally, amino acid additions to the production medium have a direct effect on the pneumocandins produced by the fermentation. Supplementation ofthe production medium with proline, trans-3- hydroxyproline and tr ⁇ «s-4-hydroxyproline effects the incorporation of trans-3 or tr ⁇ n.s-4-hydroxyproline residues in Compound I. The addition of threonine to the fermentation controls the level ofthe serine analogue, Compound IV.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

An improved process for preparing the compound of formula (I) is disclosed which utilizes certain amino acids and divalent cations such as nickel, cobalt and zinc to increase titer and decrease the amount of structural analogues.

Description

TITLE OF THE INVENTION
METHOD FOR THE PRODUCTION OF AN ANTIBIOTIC AGENT
BACKGROUND OF THE INVENTION
The fungus Glarea lozoyensis produces a family of structurally-related, pharmaceutically-important compounds known as the pneumocandins. These acylated hexapeptides are interesting in that all the constituent amino acids contain one or more hydroxyl groups. Compound I of the formula
Figure imgf000003_0001
currently the major pneumocandin produced in this fermentation, possesses the amino acids threonine, 4-hydroxyproline, 3,4-dihydroxytyrosine, 3-hydroxyglutamine, 3- hydroxyproline, and 4,5-dihydroxyornithine in addition to a dimethylmyristate side chain. Moreover, differences in the hydroxylation and amino acid substitution patterns result in over ten biosynthetically derived pneumocandins. The rate of synthesis of compound I and the levels of the structural analogues are affected by certain amino acid supplementations, certain trace elements, and osmolarity. The present invention relates to an improved process for the production of compound I, as well as certain other findings relating to the use of certain amino acids and trace elements. Compound I is disclosed in U.S. Patent No. 5,202,309 which issued
April 13, 1993. Compound I is produced by cultivating the fungus Glarea lozoyensis (formerly identified as Zalerion arboricola) under aerobic conditions. A process for the production of Compound I is disclosed in U.S. Patent 5,194,377 which issued March 16, 1993. Compound I is produced by cultivating Glarea lozoyensis, ATCC No. 20868, deposited under the Budapest Treaty in the Culture Collection of the American Type Culture Collection at 12301 Parklawn Drive, Rockville, Md. 20852.
SUMMARY OF THE INVENTION
The present invention relates to an improved process for the production of Compound I of the formula
Figure imgf000004_0001
There are also disclosed novel compounds which are structural analogues of Compound I produced during the fermentation of Compound I. These include compounds of the formula
Figure imgf000005_0001
wherein substituents Ri to Rfi are as defined below:
COMPOUND R, R2 R3 R4 R5 Rδ
II OH H CH3 OH H OH
III OH =O CH3 OH H OH rv OH OH H OH H OH
V OH OH CH3 H H OH
VI OH OH CH3 OH H H
VII H H CH3 OH OH OH
Other structural analogues are known in the art and include compounds of the formula
Figure imgf000006_0001
wherein substituents Ri to Rfi are as defined below:
COMPOUND Ri R2 R3 R4 R5 R6 vm H OH CH3 OH H OH
IX H H CH3 OH H OH
X OH OH CH3 OH OH H
XI OH OH CH3 OH OH OH
XII OH OH CH3 OH CH3 OH
Each of the compounds (II-XII) exhibits antifungal activity.
The invention also relates to the use of certain amino acids, trace elements and sugar content to enhance the production of Compound I and impact the production of certain analogue impurities.
In the production of Compound I, it has been found that certain trace elements such as divalent cations preferably zinc and cobalt, which are known to be inhibitors of α-ketoglutarate-linked dioxygenases, reduced the titer of Compound I and increased the levels of structural analogues which possess altered proline, ornithine and tyrosine hydroxylation patterns. Nickel, which is also an inhibitor of α-ketoglutarate-linked dioxygenases, has no effect on the Compound I titer but altered the hydroxylation pattern of the tyrosine residue.
Thus, certain amino acids and trace elements impact the fermentation of Compound I. In particular, supplementation of the fermentation media with the amino acid threonine controls the level of the serine analogue, Compound IV.
Culture
The fungus Glarea lozoyensis (ATCC 74030) is used to produce Compound I and the structurally related analogues. This improved production strain was derived ultimately from the wild-type organism, ATCC 20868, (isolated from a sample of fresh water) by sequential steps of N-methyl-N'-nitro-iV-nitrosoguanidme mutagenesis. The culture was maintained as aliquots of a mycelial suspension in 5% (v/v) glycerol stored at -70°C.
Seed and Production Media
The compositions of the seed and production media can be composed of a variety of carbon sources, nitrogen sources, inorganic salts, and trace nutrients in a variety of proportions. Where applicable these nutrients can be organic or inorganic, simple or complex. Each nutrient is present at a concentration appropriate and in proportion to the other nutrients in the medium. Typical useful seed and production media are listed below in Table 1 and Table 2.
Table 1 : LYCP-5 seed medium
Figure imgf000008_0001
Adjust pH to 6.0, sterilize 25 minutes at 121 °C
Table 2: FGY production medium
Figure imgf000009_0001
Adjust pH to 5.5, sterilize 30 minutes at 121°C
The following examples illustrate the invention but are not to be construed as limiting the invention disclosed herein.
EXAMPLE 1
Shake-Flask Scale Fermentations
Control Process
A 250 ml Erlenmeyer flask containing 50 ml of LYCP-5 medium was inoculated aseptically with 1 ml of a thawed culture stock. This first stage seed culture was incubated at 25°C with 220 rpm agitation for 3-5 days. A 1 ml aliquot of the first stage seed was transferred to a second 250 ml Erlenmeyer flask containing 50 ml of LYCP-5 medium. This second stage seed culture was incubated as above for 3 days.
For each variable tested (i.e., treatment group), several 250 ml Erlenmeyer flasks each containing 25 ml FGY medium or a variation thereof (described below) were inoculated at 5% (v/v) with second stage seed. The flasks were incubated at 25°C with 220 rpm agitation for 14 days. The pH for each treatment group was adjusted as required by removing one flask from the group, adding acid or base to return the pH to 5.0-5.5, and then adding this same volume of sterile titrant to the remaining flasks in the group. Where required, a volume of a sterile fructose solution was added during the fermentation to maintain the residual concentration within a specific range. Analysis of the pneumocandins produced was carried out by extracting the whole broth with organic solvent followed by chromatographic analysis using standard reverse phase and normal phase procedures. The titer of Compound I is expressed as arbitrary "units". The levels of the structural analogues is expressed as a ratio percent of the amount of Compound I produced.
Amino Acid Supplementation
On or about day 6 (i.e., mid-cycle) of the fermentation, sterile solutions of L-proline, trαrø-3-hydroxy-L-proline, trøws-4-hydroxy-L-proline, threonine, serine, arginine, ornithine or glutamine were added to the fermentation to give appropriate final concentrations. Pneumocandin extraction and analysis was carried out after 14 days of fermentation.
Increasing the proline concentration in the base medium (0-15 gm/1) resulted in a dose-dependent reduction in the levels of Compounds X and XI while the level of Compound VI increased as a function of proline concentration (Table 3).
A 15 gm/1 addition of proline to each of these treatments on or around day 6 resulted in comparable titers for each treatment but was unable to off-set the effects of the initial level of proline in the medium. Table 3: Effect of varying the initial proline concentration in the base medium
Figure imgf000011_0001
The mid-cycle addition of hydroxyprolines impacted the fermentation as well (Table 4). A 5 gm/L addition of trα«5-3-hydroxy-L-proline resulted in a 50% improvement in titer with the levels of Compounds X, VI and XI reduced dramatically. Conversely, a 5 gm/L addition of tra«s-4-hydroxy-L-proline resulted in a doubling of the level of Compound X with minimum impact on the other analogues or the titer of Compound I.
Table 4: Effect of 15 gm/L trans-3 and tra«s-4-hydroxyproline added on or about day 6
Figure imgf000011_0002
Amino acids such as glutamine, arginine, and ornithine which can be metabolized to Δ -pyrroline-5-carboxylate (P5C) also appear to have an impact on the analogues which are defined by the specific amino acid incorporated at the position "occupied" by 3-hydroxyproline in Compound I (Table 5). Table 5: Effect of proline "related" amino acids added (5 gm/L) on or about day 6.
Figure imgf000012_0001
Supplementation of the medium with 5 gm/L threonine or serine resulted in a complete elimination or large increase in the level of Compound IV respectively (Table 6). In both cases, the titer of Compound I was reduced by 30%. Additional work has shown that 1 gm/L threonine is sufficient to maintain Compound IV at acceptable levels while having no impact on the titer of Compound I.
Table 6: Effect of adding 5 gm/L serine or threonine on or about day 6
Figure imgf000012_0002
Effect of Trace Elements
Several trace elements were examined for their impact on the titer of Compound I and the spectrum of structural analogues produced. When added at concentrations equal to the ferrous salt, zinc, cobalt, and nickel salts had the most pronounced effects (Table 7). Zinc reduced the titer of Compound I by 50% and doubled the level of Compound VI. Cobalt affected a 25% reduction in the titer of Compound I while increasing the levels of Compounds VI, VIII, IX and V. The addition of nickel had no impact on the titer of Compound I but increased the level of Compound V. Table 7: Effects of trace elements
Figure imgf000013_0001
Osmolarity
In this fermentation, osmolarity can be controlled by maintaining the residual fructose concentration at high (>75 gm/L) or low (<30 gm/L). The initial fructose concentration in the control process is 125 gm/L and is kept high by making two 50 gm/L additions during the 14 cycle. Alternatively, the initial fructose concentration can be lowered to 40 gm/L and several 25 gm/L additions made during the course of the fermentation to maintain a low residual sugar level. When the "low" fructose process is run, there is a increase in the titer of Compound I along with an increase in the level of Compound X (Table 8). This increase in the level of Compound X can be offset by adding an inorganic salt such as sodium chloride or sodium sulfate. The addition of inorganic reduces the effects of running at a reduced concentration of fructose. These results suggest that osmolarity plays a role in pneumocandin synthesis.
Table 8: Effect of osmolarity
Figure imgf000013_0002
Figure imgf000014_0001
In summary, hydroxylation patterns of amino acids of Compound I are sensitive to zinc, cobalt and nickel. Additionally, amino acid additions to the production medium have a direct effect on the pneumocandins produced by the fermentation. Supplementation ofthe production medium with proline, trans-3- hydroxyproline and trα«s-4-hydroxyproline effects the incorporation of trans-3 or trαn.s-4-hydroxyproline residues in Compound I. The addition of threonine to the fermentation controls the level ofthe serine analogue, Compound IV.
Thus, the impact of amino acids and trace elements on the fermentation provides insights into factors affecting the biosynthesis of Compound I and has provided for an improved fermentation process by decreasing the levels of structural analogue and increasing the titer of Compound I.

Claims

WHAT IS CLAIMED IS:
1. A method for producing the compound of the formula
Figure imgf000015_0001
which comprises cultivating Glarea lozoyensis, ATCC 20868, in a nutrient medium containing a high residual sugar concentration, trace elements, proline, and threonine in order to control the production of structural analogues.
2. The method of Claim 1 wherein the trace elements are selected from zinc, cobalt, nickel, iron, molybdenum, calcium, boron, copper and manganese.
3. The method of Claim 2 wherein the trace elements are selected from zinc, cobalt and nickel.
4. The method of Claim 1 wherein the concentration of proline in the nutrient medium is varied from 0-15gm/l.
5. The method of Claim 1 wherein the nutrient medium is supplemented with trans-3 and trans-4 hydroxyproline.
The method of Claim 1 wherein amino acids which can be metabolized to Δ -pyrroline-5-carboxylate (P5C) are added.
7. The method of Claim 6 wherein the added amino acids are arginine, ornithine or glutamine.
8. A compound ofthe formula
Figure imgf000016_0001
wherein substituents R\ to R6 are as indicated in the table below:
Compound Ri R2 R3 R, R5 R6
II OH H CH3 OH H OH
III OH =O CH3 OH H OH rv OH OH H OH H OH
V OH OH CH3 H H OH
VI OH OH CH3 OH H H
VII H H CH3 OH OH OH
or a pharmaceutically acceptable salt thereof.
9. A method of treating fungal infections comprising administering an effective amount of a compound as defined in Claim 8, or a pharmaceutically acceptable salt thereof.
PCT/US1999/017444 1998-08-07 1999-08-04 Method for the production of an antibiotic agent WO2000008197A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP99938933A EP1100947A4 (en) 1998-08-07 1999-08-04 Method for the production of an antibiotic agent
JP2000563820A JP2003510245A (en) 1998-08-07 1999-08-04 How to make antibiotics
AU53311/99A AU5331199A (en) 1998-08-07 1999-08-04 Method for the production of an antibiotic agent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9569198P 1998-08-07 1998-08-07
US60/095,691 1998-08-07

Publications (1)

Publication Number Publication Date
WO2000008197A1 true WO2000008197A1 (en) 2000-02-17

Family

ID=22253174

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/017444 WO2000008197A1 (en) 1998-08-07 1999-08-04 Method for the production of an antibiotic agent

Country Status (4)

Country Link
EP (1) EP1100947A4 (en)
JP (1) JP2003510245A (en)
AU (1) AU5331199A (en)
WO (1) WO2000008197A1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1908770A1 (en) 2000-12-18 2008-04-09 Cubist Pharmaceuticals, Inc. Methods for preparing purified lipopeptides
WO2009158034A1 (en) * 2008-06-25 2009-12-30 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Caspofungin free of caspofungin impurity a
EP2159229A1 (en) 2000-01-20 2010-03-03 Cubist Pharmaceuticals, Inc. High purity lipopeptides, lipopeptide micelles and processes for preparing same
WO2011035492A1 (en) * 2009-09-24 2011-03-31 上海天伟生物制药有限公司 High yield antibiotics producing fungus strain, preparation method and use thereof
WO2011120842A1 (en) 2010-03-29 2011-10-06 Dsm Ip Assets B.V. Purification of caspofungin intermediates
WO2013104576A1 (en) 2012-01-13 2013-07-18 Dsm Sinochem Pharmaceuticals Netherlands B.V. Cyclopeptide fermentation at increased metal ion concentration
CN105481952A (en) * 2014-12-24 2016-04-13 上海天伟生物制药有限公司 Nitrogen-heterocycle-hexapeptide-precursor-containing compositions and preparation method and use thereof
CN106755223A (en) * 2017-01-20 2017-05-31 信泰制药（苏州）有限公司 A kind of fermentation process of Pneumocandin B0
CN107201316A (en) * 2017-07-14 2017-09-26 浙江海正药业股份有限公司 A kind of Aspergillus and its production lung read rhzomorph B0Method
CN113046250A (en) * 2019-12-27 2021-06-29 上海医药工业研究院 Production of pneumocandin B0Genetically engineered bacterium, and preparation method and application thereof
CN113046251A (en) * 2019-12-27 2021-06-29 上海医药工业研究院 Genetically engineered bacterium for producing pneumocandin B0, preparation method and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931352A (en) * 1987-10-07 1990-06-05 Merck & Co., Inc. Antifungal fermentation product
US4968608A (en) * 1987-10-07 1990-11-06 Merck & Co., Inc. Process for antifungal fermentation product
US5021341A (en) * 1990-03-12 1991-06-04 Merck & Co., Inc. Antibiotic agent produced by the cultivation of Zalerion microorganism in the presence of mannitol
US5049546A (en) * 1990-03-19 1991-09-17 Merck & Co., Inc. Antibiotic agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931352A (en) * 1987-10-07 1990-06-05 Merck & Co., Inc. Antifungal fermentation product
US4968608A (en) * 1987-10-07 1990-11-06 Merck & Co., Inc. Process for antifungal fermentation product
US5021341A (en) * 1990-03-12 1991-06-04 Merck & Co., Inc. Antibiotic agent produced by the cultivation of Zalerion microorganism in the presence of mannitol
US5049546A (en) * 1990-03-19 1991-09-17 Merck & Co., Inc. Antibiotic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1100947A4 *

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2940036A1 (en) 2000-01-20 2015-11-04 Cubist Pharmaceuticals, Inc. High purity lipopeptides, lipopeptide micelles and processes for preparing same
EP2159229A1 (en) 2000-01-20 2010-03-03 Cubist Pharmaceuticals, Inc. High purity lipopeptides, lipopeptide micelles and processes for preparing same
EP2264047A1 (en) 2000-01-20 2010-12-22 Cubist Pharmaceuticals, Inc. High purity lipopeptides, lipopeptide micelles and processes for preparing same
EP2940034A1 (en) 2000-01-20 2015-11-04 Cubist Pharmaceuticals, Inc. Process for the purification of daptomycin
EP2261237A2 (en) 2000-12-18 2010-12-15 Cubist Pharmaceuticals, Inc. Daptomycin and related analogs in crystalline form, their preparation and use
EP1908770A1 (en) 2000-12-18 2008-04-09 Cubist Pharmaceuticals, Inc. Methods for preparing purified lipopeptides
WO2009158034A1 (en) * 2008-06-25 2009-12-30 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Caspofungin free of caspofungin impurity a
WO2011035492A1 (en) * 2009-09-24 2011-03-31 上海天伟生物制药有限公司 High yield antibiotics producing fungus strain, preparation method and use thereof
KR101222233B1 (en) 2009-09-24 2013-01-16 샹하이 테크웰 바이오파마슈티컬 컴퍼니, 리미티드 High-yield antibiotics producing fungus strain, preparation method and use thereof
US8431383B2 (en) 2009-09-24 2013-04-30 Shanghai Techwell Biopharmaceutical Co., Ltd. Mutagenized strain of Glarea lozoyensis and a method of preparing a compound from the mutagenized strain
RU2507252C2 (en) * 2009-09-24 2014-02-20 Шанхай Техвелл Биофармасьютикал Ко., Лтд. Glarea lozoyensis MUTANT STRAIN AND ITS APPLICATION
WO2011120842A1 (en) 2010-03-29 2011-10-06 Dsm Ip Assets B.V. Purification of caspofungin intermediates
CN104145021A (en) * 2012-01-13 2014-11-12 中化帝斯曼制药有限公司荷兰公司 Cyclopeptide fermentation at increased metal ion concentration
WO2013104576A1 (en) 2012-01-13 2013-07-18 Dsm Sinochem Pharmaceuticals Netherlands B.V. Cyclopeptide fermentation at increased metal ion concentration
CN105481952A (en) * 2014-12-24 2016-04-13 上海天伟生物制药有限公司 Nitrogen-heterocycle-hexapeptide-precursor-containing compositions and preparation method and use thereof
KR20170120575A (en) * 2014-12-24 2017-10-31 샹하이 테크웰 바이오파마슈티컬 컴퍼니, 리미티드 Compositions Containing Nitrogen Heterocyclic Hexapeptide Precursors and Their Preparation and Use
KR102011855B1 (en) 2014-12-24 2019-08-19 샹하이 테크웰 바이오파마슈티컬 컴퍼니, 리미티드 Compositions Containing Nitrogen Heterocyclic Hexapeptide Precursors and Methods and Uses of the Same
CN106755223A (en) * 2017-01-20 2017-05-31 信泰制药（苏州）有限公司 A kind of fermentation process of Pneumocandin B0
CN107201316A (en) * 2017-07-14 2017-09-26 浙江海正药业股份有限公司 A kind of Aspergillus and its production lung read rhzomorph B0Method
CN107201316B (en) * 2017-07-14 2020-04-07 海正药业(杭州)有限公司 Aspergillus and producing pneumocandin B thereof0Method (2)
CN113046250A (en) * 2019-12-27 2021-06-29 上海医药工业研究院 Production of pneumocandin B0Genetically engineered bacterium, and preparation method and application thereof
CN113046251A (en) * 2019-12-27 2021-06-29 上海医药工业研究院 Genetically engineered bacterium for producing pneumocandin B0, preparation method and application thereof
CN113046250B (en) * 2019-12-27 2023-01-24 上海医药工业研究院 Production of pneumocandin B 0 Genetically engineered bacterium, and preparation method and application thereof
CN113046251B (en) * 2019-12-27 2023-01-24 上海医药工业研究院 Production of pneumocandin B 0 The gene engineering bacterium, its preparation method and application

Also Published As

Publication number Publication date
EP1100947A1 (en) 2001-05-23
EP1100947A4 (en) 2001-09-05
AU5331199A (en) 2000-02-28
JP2003510245A (en) 2003-03-18

Similar Documents

Publication Publication Date Title
WO2000008197A1 (en) Method for the production of an antibiotic agent
JP3061863B2 (en) Macrocyclic lactone compound and method for producing the same
EP0204179B1 (en) Method for selectively increasing the ratio of single major components of teicoplanin a2 complex
EP1355920B1 (en) Extractive purification of lipopeptide antibiotics
US5334517A (en) Microbial process for the production of trans-4-hydroxy-L-proline
Kanda et al. Improvement of FR901379 production by mutant selection and medium optimization
PICCOLI et al. Gibberellin production by Azospirillum lipoferum cultured in chemically-defined medium as affected by oxygen availability and water status
EP0769064B1 (en) A method for mass production of taxol by semi-continuous culture
Ramsey et al. Kainic acid and 1′‐hydroxykainic acid from palmariales
DE2528984C3 (en) Bestatin, its use and process for its production
CN111718863B (en) Method for producing leap-year-old mycin by fermentation
US5882900A (en) Process for the selective increase of production of antibiotic GE 2270 factor a by adding vitamin B12 to nutrient medium
CN109608523B (en) Production process of high-purity teicoplanin
FI101402B (en) A method for preparing a new antibiotic, balhimycin
AU2012213854A1 (en) Method for preparing cyclic lipopeptide compound
JPS6010720B2 (en) Production method of antibiotic C-15003 P-4
US5021549A (en) Physiologically active substances, probestin and prostatin and production thereof
EP0472186A2 (en) Antibiotics AB-023 and process for preparing them
CA2144331C (en) Process for the selective increase of production of antibiotic ge 2270 factor a
CH664758A5 (en) METHOD FOR THE PRODUCTION OF CLAVIN MOTHERGRAIN ALKALOIDS.
JP3066273B2 (en) 5-Aminolevulinic acid producing microorganism
JPS6144841A (en) 1-hydroxycitrodines and microbial manufacture
JPH04321698A (en) Physiologically active substance m6124 and production thereof
JP2886550B2 (en) Method for producing 5&#39;-inosinic acid by fermentation method
CA1082626A (en) Antibiotics sf-1771 from streptomyces

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AU AZ BA BB BG BR BY CA CN CR CU CZ EE GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1999938933

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999938933

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999938933

Country of ref document: EP